John S. Strader

906 total citations · 1 hit paper
7 papers, 706 citations indexed

About

John S. Strader is a scholar working on Molecular Biology, Hematology and Oncology. According to data from OpenAlex, John S. Strader has authored 7 papers receiving a total of 706 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Molecular Biology, 6 papers in Hematology and 1 paper in Oncology. Recurrent topics in John S. Strader's work include Multiple Myeloma Research and Treatments (6 papers), Protein Degradation and Inhibitors (5 papers) and Ubiquitin and proteasome pathways (4 papers). John S. Strader is often cited by papers focused on Multiple Myeloma Research and Treatments (6 papers), Protein Degradation and Inhibitors (5 papers) and Ubiquitin and proteasome pathways (4 papers). John S. Strader collaborates with scholars based in United States, Germany and Netherlands. John S. Strader's co-authors include Peter M. Voorhees, Robert Z. Orlowski, Deborah J. Kuhn, Qing Chen, Fijs W. B. van Leeuwen, Asher Chanan‐Khan, Susan D. Demo, Mark K. Bennett, Congcong Sun and Kevin D. Shenk and has published in prestigious journals such as Blood and Clinical Cancer Research.

In The Last Decade

John S. Strader

7 papers receiving 689 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma

2007 591 citations Deborah J. Kuhn, Qing Chen et al. Blood profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
John S. Strader United States	4	582	384	275	54	53	7	706
Tina M. Woo United States	7	620 1.1×	380 1.0×	269 1.0×	61 1.1×	39 0.7×	13	751
Denise Niewerth Netherlands	12	530 0.9×	322 0.8×	240 0.9×	41 0.8×	59 1.1×	20	697
K. Martin Kortuem United States	10	667 1.1×	557 1.5×	276 1.0×	79 1.5×	65 1.2×	20	853
Soraya Wuillème‐Toumi France	5	467 0.8×	230 0.6×	151 0.5×	37 0.7×	75 1.4×	6	553
Jana L. Dawson United States	11	658 1.1×	230 0.6×	211 0.8×	36 0.7×	41 0.8×	26	778
Emmanuelle Ménoret France	10	444 0.8×	194 0.5×	160 0.6×	45 0.8×	119 2.2×	14	574
Maria Alessandra Santucci Italy	17	432 0.7×	296 0.8×	136 0.5×	112 2.1×	40 0.8×	49	740
Bangzheng Chen United States	6	584 1.0×	430 1.1×	320 1.2×	62 1.1×	155 2.9×	8	900
Kerstin Maria Kampa-Schittenhelm Germany	12	283 0.5×	155 0.4×	171 0.6×	80 1.5×	90 1.7×	30	516
Nelida Sjak-Shie United States	12	367 0.6×	295 0.8×	244 0.9×	42 0.8×	88 1.7×	16	596

Countries citing papers authored by John S. Strader

Since Specialization

Citations

This map shows the geographic impact of John S. Strader's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John S. Strader with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John S. Strader more than expected).

Fields of papers citing papers by John S. Strader

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John S. Strader. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John S. Strader. The network helps show where John S. Strader may publish in the future.

Co-authorship network of co-authors of John S. Strader

This figure shows the co-authorship network connecting the top 25 collaborators of John S. Strader. A scholar is included among the top collaborators of John S. Strader based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John S. Strader. John S. Strader is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

7 of 7 papers shown

1.

Voorhees, Peter M., Cristina Gasparetto, Keren Osman, et al.. (2011). Vorinostat in Combination with Pegylated Liposomal Doxorubicin (PLD) and Bortezomib (B) in Patients with Relapsed/Refractory Multiple Myeloma (R/R MM): Final Results of a Phase I Study,. Blood. 118(21). 3985–3985. 3 indexed citations

2.

Voorhees, Peter M., Cristina Gasparetto, Keren Osman, et al.. (2010). Results of a Phase I Study of Vorinostat In Combination with Pegylated Liposomal Doxorubicin and Bortezomib In Patients with Relapsed/Refractory Multiple Myeloma. Blood. 116(21). 1955–1955. 9 indexed citations

3.

Voorhees, Peter M., Cristina Gasparetto, Kristy L. Richards, et al.. (2009). Vorinostat in Combination with Pegylated Liposomal Doxorubicin and Bortezomib for Patients with Relapsed/Refractory Multiple Myeloma: Results of a Phase I Study.. Blood. 114(22). 306–306. 6 indexed citations

4.

Voorhees, Peter M., Qing Chen, Deborah J. Kuhn, et al.. (2007). Inhibition of Interleukin-6 Signaling with CNTO 328 Enhances the Activity of Bortezomib in Preclinical Models of Multiple Myeloma. Clinical Cancer Research. 13(21). 6469–6478. 93 indexed citations

5.

Kuhn, Deborah J., Qing Chen, Peter M. Voorhees, et al.. (2007). Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. Blood. 110(9). 3281–3290. 591 indexed citations breakdown →

6.

Kuhn, Deborah J., Peter M. Voorhees, Qing Chen, et al.. (2006). Development of Immunoproteasome-Specific Inhibitors as Novel Anti-Cancer Drugs.. Blood. 108(11). 3458–3458. 1 indexed citations

7.

Kuhn, Deborah J., Peter M. Voorhees, John S. Strader, et al.. (2005). Potent Activity of a Novel, Irreversible Inhibitor of the Ubiquitin-Proteasome Pathway Against Pre-Clinical Models of Multiple Myeloma.. Blood. 106(11). 1576–1576. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact